KR101010284B1 - Phsrn-rgd 포함 올리고펩타이드를 유효성분으로 함유하는 골형성 촉진용 조성물 - Google Patents
Phsrn-rgd 포함 올리고펩타이드를 유효성분으로 함유하는 골형성 촉진용 조성물 Download PDFInfo
- Publication number
- KR101010284B1 KR101010284B1 KR1020070066935A KR20070066935A KR101010284B1 KR 101010284 B1 KR101010284 B1 KR 101010284B1 KR 1020070066935 A KR1020070066935 A KR 1020070066935A KR 20070066935 A KR20070066935 A KR 20070066935A KR 101010284 B1 KR101010284 B1 KR 101010284B1
- Authority
- KR
- South Korea
- Prior art keywords
- bone
- composition
- oligopeptide
- support
- bone formation
- Prior art date
Links
- 108010038807 Oligopeptides Proteins 0.000 title claims abstract description 41
- 102000015636 Oligopeptides Human genes 0.000 title claims abstract description 41
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 230000011164 ossification Effects 0.000 title claims abstract description 22
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 64
- 239000000463 material Substances 0.000 claims abstract description 25
- 230000001737 promoting effect Effects 0.000 claims abstract description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 9
- 210000001519 tissue Anatomy 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 14
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 9
- 239000000377 silicon dioxide Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 5
- 239000001506 calcium phosphate Substances 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 3
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 3
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 3
- 239000004626 polylactic acid Substances 0.000 claims description 3
- 229910052719 titanium Inorganic materials 0.000 claims description 3
- 239000010936 titanium Substances 0.000 claims description 3
- 229910052586 apatite Inorganic materials 0.000 claims description 2
- 229920000249 biocompatible polymer Polymers 0.000 claims description 2
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 229910000150 monocalcium phosphate Inorganic materials 0.000 claims description 2
- 235000019691 monocalcium phosphate Nutrition 0.000 claims description 2
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 claims description 2
- 235000012239 silicon dioxide Nutrition 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 2
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 108010067306 Fibronectins Proteins 0.000 abstract description 19
- 102000016359 Fibronectins Human genes 0.000 abstract description 19
- 210000000963 osteoblast Anatomy 0.000 abstract description 15
- 230000004069 differentiation Effects 0.000 abstract description 10
- 230000010478 bone regeneration Effects 0.000 abstract description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract description 5
- 230000021164 cell adhesion Effects 0.000 abstract description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 abstract description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 abstract description 3
- 210000002744 extracellular matrix Anatomy 0.000 abstract description 3
- 230000000699 topical effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 22
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical group NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 14
- 108010039042 prolyl-histidyl-seryl-arginyl-asparagine Proteins 0.000 description 13
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 12
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 12
- 241000700159 Rattus Species 0.000 description 10
- 230000007547 defect Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 102000006495 integrins Human genes 0.000 description 9
- 108010044426 integrins Proteins 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 8
- 210000003625 skull Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 239000007943 implant Substances 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 108010061238 threonyl-glycine Proteins 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 201000008968 osteosarcoma Diseases 0.000 description 3
- 230000003239 periodontal effect Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- OMSKGWFGWCQFBD-KZVJFYERSA-N Ala-Val-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OMSKGWFGWCQFBD-KZVJFYERSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- FKESCSGWBPUTPN-FOHZUACHSA-N Gly-Thr-Asn Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O FKESCSGWBPUTPN-FOHZUACHSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- KLSUAWUZBMAZCL-RHYQMDGZSA-N Leu-Thr-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(O)=O KLSUAWUZBMAZCL-RHYQMDGZSA-N 0.000 description 2
- ZOPISOXXPQNOCO-SVSWQMSJSA-N Ser-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CO)N ZOPISOXXPQNOCO-SVSWQMSJSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 230000004072 osteoblast differentiation Effects 0.000 description 2
- 230000002138 osteoinductive effect Effects 0.000 description 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108010029020 prolylglycine Proteins 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- SEFVRKXJJPMVHQ-YUMQZZPRSA-N (2s)-2-[[2-[[(2s)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]butanedioic acid Chemical compound NC(N)=NCCC[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O SEFVRKXJJPMVHQ-YUMQZZPRSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- QTIZKMMLNUMHHU-DCAQKATOSA-N Asp-Pro-His Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC(=O)O)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O QTIZKMMLNUMHHU-DCAQKATOSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100315624 Caenorhabditis elegans tyr-1 gene Proteins 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GBYYQVBXFVDJPJ-WLTAIBSBSA-N Gly-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)CN)O GBYYQVBXFVDJPJ-WLTAIBSBSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 101000982538 Homo sapiens Inositol polyphosphate 5-phosphatase OCRL Proteins 0.000 description 1
- QHUREMVLLMNUAX-OSUNSFLBSA-N Ile-Thr-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)O)N QHUREMVLLMNUAX-OSUNSFLBSA-N 0.000 description 1
- 102100026724 Inositol polyphosphate 5-phosphatase OCRL Human genes 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- FCRMLGJMPXCAHD-FXQIFTODSA-N Ser-Arg-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O FCRMLGJMPXCAHD-FXQIFTODSA-N 0.000 description 1
- 101710151387 Serine protease 1 Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- BPGDJSUFQKWUBK-KJEVXHAQSA-N Thr-Val-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 BPGDJSUFQKWUBK-KJEVXHAQSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 101710119665 Trypsin-1 Proteins 0.000 description 1
- NZBSVMQZQMEUHI-WZLNRYEVSA-N Tyr-Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N NZBSVMQZQMEUHI-WZLNRYEVSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000316 bone substitute Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000011496 digital image analysis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 108010018006 histidylserine Proteins 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (9)
- A-L-B(상기 A는 PHSRN이고, B는 RGD이며, L은 서열번호 3으로 기재되는 아미노산으로 구성된 링커 펩타이드이다.)로 구성된 올리고펩타이드를 유효성분으로 함유하는 골형성 촉진용 조성물.
- 삭제
- 삭제
- 삭제
- 삭제
- 제 1항의 조성물이 표면에 코팅된 골형성 촉진용 골이식재.
- 제 6항에 있어서, 상기 골이식재는 생물유래 골미네랄의 분말 및 다공성 블록, 합성 수산화아파타이트의 분말 및 다공성 블록, 트리칼슘인산의 분말 및 다공성 블록, 모노칼슘인산의 분말 및 다공성 블럭, 이산화 규소(실리카)로 이루어진 골이식재, 실리카와 고분자의 혼합체로 이루어진 골충진 이식재, 키토산, 폴리락트산을 포함하는 생체적합성 고분자로 이루어진 미립자 및 다공성 지지체, 티타늄 및 3차원적 다공성 지지체로 구성된 군으로부터 선택되어지는 것을 특징으로 하는 골이식재.
- 제 1항의 조성물이 표면에 코팅된 골형성 촉진용 조직공학용 지지체.
- 제 8항에 있어서, 상기 지지체는 실리카와 고분자의 혼합체로 이루어진 골충 진 이식재, 키토산, 폴리락트산을 포함하는 생체적합성 고분자로 이루어진 미립자 및 다공성 지지체, 티타늄 및 3차원적 다공성 지지체로 구성된 군으로부터 선택되어지는 것을 특징으로 하는 조직공학용 지지체.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070066935A KR101010284B1 (ko) | 2007-07-04 | 2007-07-04 | Phsrn-rgd 포함 올리고펩타이드를 유효성분으로 함유하는 골형성 촉진용 조성물 |
US11/967,132 US7897722B2 (en) | 2007-07-04 | 2007-12-29 | Composition of bone formation with PHSRN-RGD containing oligopeptide |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070066935A KR101010284B1 (ko) | 2007-07-04 | 2007-07-04 | Phsrn-rgd 포함 올리고펩타이드를 유효성분으로 함유하는 골형성 촉진용 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090002736A KR20090002736A (ko) | 2009-01-09 |
KR101010284B1 true KR101010284B1 (ko) | 2011-01-24 |
Family
ID=40221623
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020070066935A KR101010284B1 (ko) | 2007-07-04 | 2007-07-04 | Phsrn-rgd 포함 올리고펩타이드를 유효성분으로 함유하는 골형성 촉진용 조성물 |
Country Status (2)
Country | Link |
---|---|
US (1) | US7897722B2 (ko) |
KR (1) | KR101010284B1 (ko) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101456642B1 (ko) * | 2012-06-20 | 2014-11-03 | 주식회사 본셀바이오텍 | 피브리노겐이 코팅된 골 분말을 포함하는 골 재생용 조성물 및 이의 제조 방법 |
KR102013218B1 (ko) * | 2019-02-01 | 2019-08-22 | 영남대학교 산학협력단 | 세포의 부착, 증식과 분화를 촉진하는 신규 펩티드 fnin2 및 이의 용도 |
KR102053895B1 (ko) * | 2019-02-01 | 2019-12-09 | 영남대학교 산학협력단 | 세포의 부착, 증식과 분화를 촉진하는 신규 펩티드 fnin3 및 이의 용도 |
WO2020159025A1 (ko) * | 2019-02-01 | 2020-08-06 | 영남대학교 산학협력단 | 세포의 부착, 증식과 분화를 촉진하는 신규 펩티드 및 이의 용도 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040081704A1 (en) | 1998-02-13 | 2004-04-29 | Centerpulse Biologics Inc. | Implantable putty material |
US20020114795A1 (en) | 2000-12-22 | 2002-08-22 | Thorne Kevin J. | Composition and process for bone growth and repair |
US7718616B2 (en) * | 2006-12-21 | 2010-05-18 | Zimmer Orthobiologics, Inc. | Bone growth particles and osteoinductive composition thereof |
US8613938B2 (en) | 2010-11-15 | 2013-12-24 | Zimmer Orthobiologics, Inc. | Bone void fillers |
DE102016222603A1 (de) * | 2016-11-16 | 2018-05-17 | Aesculap Ag | Implantat und ein Kit zum Behandeln eines Knochendefekts |
US20190105800A1 (en) * | 2017-10-06 | 2019-04-11 | Alex Xie | Method and apparatus for forming marbelized engineered stone |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030088257A (ko) * | 2002-05-14 | 2003-11-19 | 구영 | 세포에 부착하는 올리고펩타이드 |
-
2007
- 2007-07-04 KR KR1020070066935A patent/KR101010284B1/ko active IP Right Grant
- 2007-12-29 US US11/967,132 patent/US7897722B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030088257A (ko) * | 2002-05-14 | 2003-11-19 | 구영 | 세포에 부착하는 올리고펩타이드 |
Non-Patent Citations (1)
Title |
---|
Biomaterials, Vol.26, pp5209-5220 (2005)* |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101456642B1 (ko) * | 2012-06-20 | 2014-11-03 | 주식회사 본셀바이오텍 | 피브리노겐이 코팅된 골 분말을 포함하는 골 재생용 조성물 및 이의 제조 방법 |
KR102013218B1 (ko) * | 2019-02-01 | 2019-08-22 | 영남대학교 산학협력단 | 세포의 부착, 증식과 분화를 촉진하는 신규 펩티드 fnin2 및 이의 용도 |
KR102053895B1 (ko) * | 2019-02-01 | 2019-12-09 | 영남대학교 산학협력단 | 세포의 부착, 증식과 분화를 촉진하는 신규 펩티드 fnin3 및 이의 용도 |
WO2020159025A1 (ko) * | 2019-02-01 | 2020-08-06 | 영남대학교 산학협력단 | 세포의 부착, 증식과 분화를 촉진하는 신규 펩티드 및 이의 용도 |
Also Published As
Publication number | Publication date |
---|---|
US7897722B2 (en) | 2011-03-01 |
KR20090002736A (ko) | 2009-01-09 |
US20090010988A1 (en) | 2009-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101010284B1 (ko) | Phsrn-rgd 포함 올리고펩타이드를 유효성분으로 함유하는 골형성 촉진용 조성물 | |
Xia et al. | RGD-and VEGF-mimetic peptide epitope-functionalized self-assembling peptide hydrogels promote dentin-pulp complex regeneration | |
Itoh et al. | Enhancement of osteogenesis on hydroxyapatite surface coated with synthetic peptide (EEEEEEEPRGDT) in vitro | |
Gungormus et al. | Self assembled bi-functional peptide hydrogels with biomineralization-directing peptides | |
EP2446862B1 (en) | Amphiphilic peptides and hydrogel matrices thereof for bone repair | |
Zhou et al. | Improving osteogenesis of three-dimensional porous scaffold based on mineralized recombinant human-like collagen via mussel-inspired polydopamine and effective immobilization of BMP-2-derived peptide | |
Choi et al. | The identification of a heparin binding domain peptide from bone morphogenetic protein-4 and its role on osteogenesis | |
US8846860B2 (en) | Methods of decorating hydroxyapatite biomaterials with modular biologically active molecules | |
US6632790B1 (en) | Laminin 2 and methods for its use | |
US7897727B2 (en) | Bioactive peptide for cell adhesion | |
Zhao et al. | D-RADA16-RGD-reinforced nano-hydroxyapatite/polyamide 66 ternary biomaterial for bone formation | |
Zamuner et al. | Smart biomaterials: Surfaces functionalized with proteolytically stable osteoblast-adhesive peptides | |
Choi et al. | The mineralization inducing peptide derived from dentin sialophosphoprotein for bone regeneration | |
Zhang et al. | Designer self-assembling peptide scaffold stimulates pre-osteoblast attachment, spreading and proliferation | |
CN114377202B (zh) | 适用于软骨再生的功能化自组装miRNA/多肽复合水凝胶及其制备方法 | |
Huang et al. | Engineering a self-assembling leucine zipper hydrogel system with function-specific motifs for tissue regeneration | |
Tian et al. | Effects of a novel self‐assembling peptide scaffold on bone regeneration and controlled release of two growth factors | |
Liu et al. | Functionalized self-assembled peptide RAD/Dentonin hydrogel scaffold promotes dental pulp regeneration | |
Zamuner et al. | Biofunctionalization of bioactive ceramic scaffolds to increase the cell response for bone regeneration | |
WO1999054359A1 (en) | Matrix binding factor | |
KR100885071B1 (ko) | 세포에 부착하는 올리고펩타이드 | |
KR101348096B1 (ko) | 줄기세포의 연골 분화 유도 활성을 가지는 폴리펩타이드 | |
Chairperson et al. | Session 1: Collagen Cross-Linking and Biomineralization | |
CN110072877B (zh) | 具有钛结合能力的肽 | |
WO2014130517A2 (en) | Modular, bioactive peptides for binding native bone and improving bone graft osteoinductivity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
J201 | Request for trial against refusal decision | ||
B601 | Maintenance of original decision after re-examination before a trial | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20090309 Effective date: 20100628 |
|
S901 | Examination by remand of revocation | ||
E902 | Notification of reason for refusal | ||
GRNO | Decision to grant (after opposition) | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20140106 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20150106 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20151224 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20161227 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20171221 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20190102 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20200102 Year of fee payment: 10 |